Kailera Therapeutics develops next-generation injectable and oral therapies for chronic weight management.
Kailera Therapeutics has raised $600.0M in total funding. The most recent round was Series B. The last funding was announced in October 2025.
Kailera Therapeutics's investors include Janus Henderson Investors, Adage Capital Management, RTW Investments, T. Rowe Price, Atlas Venture.
Kailera Therapeutics is headquartered in Waltham, United States.
Kailera Therapeutics develops next-generation injectable and oral therapies for chronic weight management.
Kailera Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Kailera Therapeutics — Funding & Investors." VCBacked, October 14, 2025, https://www.vcbacked.co/company/kailera-therapeutics. Accessed July 31, 2026.
VCBacked. (2025). Kailera Therapeutics — Funding & Investors. Retrieved July 31, 2026, from https://www.vcbacked.co/company/kailera-therapeutics
{{cite web |title=Kailera Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/kailera-therapeutics |website=VCBacked |access-date=July 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated